ReNeuron Group plc
RNUGF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.04 | 0.25 | 0.16 |
| FCF Yield | -184.83% | -46.81% | -12.59% | -39.78% |
| EV / EBITDA | 0.25 | -0.70 | -2.64 | -1.83 |
| Quality | ||||
| ROIC | -105.51% | -94.14% | -55.68% | -84.18% |
| Gross Margin | -742.08% | -1,901.99% | -3,597.67% | -169.33% |
| Cash Conversion Ratio | 1.12 | 0.67 | 0.45 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 27.29% | -59.50% | 73.75% | 420.54% |
| Free Cash Flow Growth | 0.12% | -26.92% | 57.87% | -18.42% |
| Safety | ||||
| Net Debt / EBITDA | 0.90 | 0.84 | 1.08 | 0.88 |
| Interest Coverage | -355.75 | -449.12 | -403.56 | -343.07 |
| Efficiency | ||||
| Inventory Turnover | -2.65 | -4.18 | 0.00 | -2.50 |
| Cash Conversion Cycle | 180.45 | 365.03 | 600.32 | -158.05 |